IFN-beta (mouse) (monomer):Fc (silent) InVivoKine(tm)

AdipoGen Life Sciences

IFN-beta (mouse) (monomer):Fc (silent) InVivoKine(tm)

10

Research Use Only

1 mg/ml

>95%

Ifnb1

interferon beta 1, fibroblast

IFN-beta, IFNB, If1da1, Ifb, interferon beta, interferon 1da1

Interferon beta

Interferons (IFNs) are a class of cytokines that initiate a cascade of immune responses against pathogens. During an infection, pattern recognition receptors (PRRs) sense pathogen-associated molecular patterns (PAMPs), leading to the induction and secretion of IFNs by infected immune or epithelial cells. IFNs bind IFN receptors on the surface of neighboring and/or immune cells, triggering a signaling cascade to induce a suite of IFN-stimulated genes (ISGs) that directly mediate the anti-pathogenic effects of IFNs. Each type of IFN has its own specificities, such as different receptor utilization, expression patterns and distinct downstream genes. IFN-alpha and IFN-beta are type I IFNs, produced by most cells in response to infection. Type I IFNs bind to their receptor, IFNAR, leading to the phosphorylation of transcription factors (TFs) STAT1 and STAT2, which bind IFN regulatory factor (IRF) 9 to form a complex called the ISG factor 3 (ISGF3). ISGF3 translocates to the nucleus and induces ISGs. The IFN-beta (mouse) (monomer):Fc (silent) InVivoKine™ is produced by using two different vectors, one encoding for the IFN-beta (mouse):Fc (LALA-PG) Knobs sequence (synthesizing a protein of 65-68 kDa) and one encoding for the Fc (LALA-PG) Holes sequence (synthesizing a protein of 28 kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization of the Fc moieties and for secretion of the final protein IFN-beta (mouse) (monomer):Fc (silent) InVivoKine™. The LALA-PG mutations inhibit binding to FcgammaRs and C1q, while FcRn binding and Fc stability remain unaffected. InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences. - Recombinant Protein. Mouse IFN-beta (aa 22-182) is fused at the C-terminus to the Fc portion of human IgG1 (LALA-PG) (Knobs-into-Holes technology) (see reference: J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)). Lyophilized. Contains PBS. Interferons (IFNs) are a class of cytokines that initiate a cascade of immune responses against pathogens. During an infection, pattern recognition receptors (PRRs) sense pathogen-associated molecular patterns (PAMPs), leading to the induction and secretion of IFNs by infected immune or epithelial cells. IFNs bind IFN receptors on the surface of neighboring and/or immune cells, triggering a signaling cascade to induce a suite of IFN-stimulated genes (ISGs) that directly mediate the anti-pathogenic effects of IFNs. Each type of IFN has its own specificities, such as different receptor utilization, expression patterns and distinct downstream genes. IFN-alpha and IFN-beta are type I IFNs, produced by most cells in response to infection. Type I IFNs bind to their receptor, IFNAR, leading to the phosphorylation of transcription factors (TFs) STAT1 and STAT2, which bind IFN regulatory factor (IRF) 9 to form a complex called the ISG factor 3 (ISGF3). ISGF3 translocates to the nucleus and induces ISGs. The protein IFN-beta (mouse) (monomeric):Fc (LALA-PG)-KIH (human) (rec.) is produced by using two different vectors, one encoding for the IFN-beta (mouse):Fc (LALA-PG) Knobs sequence (synthesizing a protein of 65-68 kDa) and one encoding for the Fc (LALA-PG) Holes sequence (synthesizing a protein of 28 kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization of the Fc moieties and for secretion of the final protein IFN-beta (mouse) (monomeric):Fc (LALA-PG)-KIH (human) (rec.). The LALA-PG mutations inhibit binding to FcgammaRs and C1q, while FcRn binding and Fc stability remain unaffected. InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.

-20°C,2°C to 8°C

41116100

Mouse